{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-050245","form_type":"8-K","ticker":"ADIL","cik":"0001513525","company_name":"ADIAL PHARMACEUTICALS, INC.","filed_at":"2022-08-23T23:59:59+00:00","discovered_at":"2026-05-14T18:03:55.982899+00:00","generated_at":"2026-06-23T21:58:47.376837+00:00","sec_items":["5.02","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"confidence":"high","headline":"Adial appoints Cary Claiborne as CEO and Kevin Schuyler as Chairman; Stilley named Purnovate CEO","bullets":["Cary Claiborne promoted from COO to President/CEO, base salary $450k, RSU grant of 1M shares vesting over 36 months.","Kevin Schuyler appointed non-executive Chairman; previously Vice Chairman and director since 2016.","William Stilley named CEO of Purnovate, subsidiary; base salary $260k, increasing to $430k when cash hits $3M; option for 100k shares.","Claiborne's background includes CFO at Indivior and Sucampo; Schuyler is senior MD at CornerStone Partners.","Stilley gets enhanced severance if terminated without cause before Aug 22, 2023, based on $430k base salary."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-050245","json":"https://secwatch.observer/filing/0001213900-22-050245.json","markdown":"https://secwatch.observer/filing/0001213900-22-050245.md","text":"https://secwatch.observer/filing/0001213900-22-050245.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022050245/0001213900-22-050245-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022050245/ea164799-8k_adial.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-23T21:58:47.376837+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"075e7c1047","claim":"Kevin Schuyler was appointed as non-executive Chairman at ADIAL PHARMACEUTICALS, INC..","evidence_excerpt":"On August 18, 2022, the Company’s board of directors also appointed Kevin Schuyler as non-executive Chairman of the board of directors.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022050245/0001213900-22-050245-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"non-executive Chairman"}],"fact_type":"executive_change"},{"claim_id":"106b38d4ef","claim":"Cary J. Claiborne was appointed as President and Chief Executive Officer at ADIAL PHARMACEUTICALS, INC..","evidence_excerpt":"On August 18, 2022, the board of directors of Adial Pharmaceuticals, Inc. (the “Company”) appointed Cary J. Claiborne, age 61, as President and Chief Executive Officer.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1513525/000121390022050245/0001213900-22-050245-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"President and Chief Executive Officer"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}